To confirm in vivo our observations, NK cells from MDS patients recruited in the clinical trial NCT02985190 were analyzed for their capacity to produce IFN-γ and to restore their phenotype, before and after 3 or 6 cycles of treatment with AZA. This evidence concerns the gene IFNG and myelodysplastic syndrome.